Sonoma Pharmaceuticals Inc (SNOA)

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsJune 16, 2026 4:15 PM
ACCESS NewswireRevenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025Net loss improved 25% in Q4 2026 compared to Q4 2025, and 8% in FY 2026 compared to FY 2025EBITDA loss improved 66% in Q4 2026 compared to Q4 2025, and 38% in FY 2026 compared to FY 2025 BOULDER, CO / ACCESS Newswire / June 16, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2026 and the fourth quarter ended March 31, 2026."Fiscal 2026 was a year of significant progress for Sonoma," remarked Amy Trombly, CEO of Sonoma. "We delivered strong revenue growth while continuing to improve the financial health of the business as we maintained our focus on strategic growth, operational discipline, cost management, and efficient execution. Throughout the year, we continued to expand commercial partnerships, advance regulatory initiatives, and invest in product innovation. As we look ahead, our priority remains building a stronger and more scalable business by focusing on opportunities that align with our strategic objectives, generate attractive returns, and support long-term shareholder value. We believe the growing adoption of hypochlorous acid across healthcare, consumer, and wellness markets continues to create meaningful opportunities for Sonoma, and we remain focused on translating those opportunities into sustainable growth and improved profitability."Recent Business HighlightsSonoma continued to expand its product offerings, grow its distribution network, and expand regulatory approvals for its products:In October 2025, Sonoma announced the registration of its manufacturing facility and listing of its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).Also in October 2025, Sonoma announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, to be distributed into hospital systems, home healthcare and other healthcare channels across the United States.In August 2025, Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned the National Psoriasis Foundation (NPF) Seal of Recognition, and in November 2025, Reliefacyn earned the National Rosacea Society (NRS) Seal of Acceptance.Results for the Quarter Ended March 31, 2026Total revenue of $5.6 million for the fourth quarter of fiscal year 2026 increased by $1.8 million, or 48%, from $3.8 million for the same period last year. This increase was primarily due to increased revenues in the United States, Europe and Rest of World, partially offset by declines in Asia and Latin America due to timing of customer orders. United States revenue of $2.0 million for the fourth quarter ended March 31, 2026 increased by $1.3 million, or 194%, from $0.7 million for the same period last year due to increased sales by new distributors selling our products.During the fourth quarter of fiscal year 2026, Sonoma reported total revenues of $5.6 million and total cost of revenues of $3.4 million resulting in total gross profit of $2.2 million, or 39% of total revenue, compared to a gross profit of $1.5 million, or 41% of total revenue, in the same period last year.Total operating expenses during the fourth quarter of fiscal year 2026 were $2.5 million, up $0.3 million, or 16%, as compared to the same period in the prior year. This increase was primarily due to inflation and salary-related increases in Mexico.Net loss for the fourth quarter of fiscal year 2026 was $0.6 million, down by $0.2 million, or 25%, compared to the same period last year. EBITDA loss for the fourth quarter of fiscal year 2026 of $0.2 million was down by $0.3 million, or 66%, compared to an EBITDA loss of $0.5 million for the same period last year.As of March 31, 2026, Sonoma had cash and cash equivalents of $2.4 million.Results for the Year Ended March 31, 2026Total revenues for fiscal year 2026 of $19.5 million increased by $5.2 million as compared to $14.3 million for the year ended March 31, 2025. The increase in revenue was driven primarily by increased revenues in all regions except Latin America due primarily to increased demand for our products. The decrease in Latin America was due to timing of customer orders.For fiscal year 2026, Sonoma reported total revenues of $19.5 million and total cost of revenues of $12.1 million, resulting in total gross profit of $7.4 million, or 38% of total revenues, compared to a gross profit of $5.5 million, or 38% of total revenues, for the same period in the prior year.Total operating expenses during fiscal year 2026 were $9.9 million, up $0.7 million, or 8%, as compared to the same period in the prior year. This increase was primarily due to market and inflation driven salary increases in Mexico.Net loss during fiscal year 2026 was $3.2 million, down $0.3 million, or 8%, compared to the same period last year. EBITDA loss for fiscal year 2026 of $2.1 million was down $1.2 million, or 38%, compared to an EBITDA loss of $3.3 million for the same period last year.About Sonoma Pharmaceuticals, Inc.Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The company's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact businessdevelopment@sonomapharma.com.Forward-Looking StatementsExcept for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.Media and Investor Contact:Sonoma Pharmaceuticals, Inc.ir@sonomapharma.comWebsite: www.sonomapharma.comFollow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticalsFollow us on Instagram: https://www.instagram.com/sonomapharma_us/Follow us on Facebook: https://www.facebook.com/sonomapharma/ SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts) March 31, 2026 2025 ASSETS Current assets: Cash and cash equivalents $2,399 $5,374 Accounts receivable, net 2,527 2,232 Inventories, net 3,651 2,915 Prepaid expenses and other current assets 3,436 1,915 Current portion of deferred consideration, net of discount 87 212 Total current assets 12,100 12,648 Property and equipment, net 310 225 Operating lease, right of use assets 602 84 Deferred tax asset, net 884 589 Deferred consideration, net of discount, less current portion - 73 Other assets 64 74 Total assets $13,960 $13,693 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $1,923 $953 Accrued expenses and other current liabilities 2,252 2,224 Deferred revenue, current portion 284 641 Short-term debt 222 220 Operating lease liabilities, current portion 151 58 Total current liabilities 4,832 4,096 Deferred revenue, net of current portion - 17 Withholding tax payable 5,564 5,142 Operating lease liabilities, less current portion 469 27 Total liabilities 10,865 9,282 Commitments and Contingencies Stockholders' Equity: Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2026 and 2025, respectively, no shares issued and outstanding at March 31, 2026 and 2025 - - Common stock, $0.0001 par value; 50,000,000 shares authorized at March 31, 2026 and 2025, 1,799,057 and 1,634,265 shares issued and outstanding at March 31, 2026 and 2025, respectively - - Additional paid-in capital 207,319 206,593 Accumulated deficit (200,981) (197,806)Accumulated other comprehensive loss (3,243) (4,376)Total stockholders' equity 3,095 4,411 Total liabilities and stockholders' equity $13,960 $13,693 SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share amounts) Three Months EndedMarch 31, Year EndedMarch 31, 2026 2025 2026 2025 (Unaudited) Revenues $5,561 $3,754 $19,529 $14,288 Cost of revenues 3,380 2,226 12,114 8,823 Gross profit 2,181 1,528 7,415 5,465 Operating expenses Research and development 545 411 2,271 1,814 Selling, general and administrative 1,987 1,773 7,605 7,361 Total operating expenses 2,532 2,184 9,876 9,175 Loss from operations (351) (656) (2,461) (3,710)Other (expense) income (146) 128 (958) 803 Loss before income taxes (497) (528) (3,419) (2,907)Income tax benefit (expense) (84) (248) 244 (550)Net loss $(581) $(776) $(3,175) $(3,457) Net loss per share: basic and diluted $(0.33) $(0.48) $(1.89) $(2.79)Weighted-average number of shares: basic and diluted 1,736 1,619 1,684 1,241 Other comprehensive loss Net loss $(581) $(776) $(3,175) $(3,457)Foreign currency translation adjustments (52) 178 1,133 (1,653)Comprehensive loss $(633) $(598) $(2,042) $(5,110)SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited) Three Months EndedMarch 31, Year EndedMarch 31, 2026 2025 2026 2025 (1) Loss from operations minus non-cash expenses EBITDA loss: GAAP loss from operations as reported $(351) $(656) $(2,461) $(3,710)Non-cash adjustments: Stock-based compensation 134 90 255 224 Depreciation and amortization 34 31 139 138 Non-GAAP loss from operations minus non-cash expenses EBITDA loss $(183) $(535) $(2,067) $(3,348) (2) Net loss minus non-cash and one-time expenses: GAAP net loss as reported $(581) $(776) $(3,175) $(3,457)Non-cash adjustments: Stock-based compensation 134 90 255 224 Non-cash foreign exchange transaction losses (gains) 169 162 1,446 (243)Income tax expense (benefit) 84 248 (244) 550 Depreciation and amortization 34 31 139 138 Non-GAAP net loss minus non-cash expenses $(160) $(245) $(1,579) $(2,788) (3) Operating expenses minus non-cash expenses GAAP operating expenses as reported $2,532 $2,184 $9,876 $9,175 Non-cash adjustments: Stock-based compensation (134) (90) (255) (224)Depreciation and amortization (34) (31) (139) (138)Non-GAAP operating expenses minus non-cash expenses $2,364 $2,063 $9,482 $8,813 (1)Loss from operations minus non-cash expenses (EBITDA) is a non-GAAP financial measure. The Company defines operating loss minus non-cash expenses as GAAP reported operating loss minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. . Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.(2)Net loss minus non-cash and one-time expenses is a non-GAAP financial measure. The company defines net loss minus non-cash expenses as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes, and non-cash foreign exchange transaction losses. The company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.(3)Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. . Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
REVENUE SCHEDULES
(In thousands)The following table shows the Company's revenues by geographic region: Three Months EndedMarch 31, 2026 2025 $ Change % Change (Unaudited) United States $2,002 $681 $1,321 194%Europe 1,725 1,580 145 9%Asia 381 485 (104) (21%)Latin America 759 788 (29) (4%)Rest of the World 694 220 474 215%Total $5,561 $3,754 $1,807 48% Year EndedMarch 31, 2026 2025 $ Change % Change United States $5,674 $2,611 $3,063 117%Europe 6,904 5,523 1,381 25%Asia 2,900 2,317 583 25%Latin America 2,373 2,962 (589) (20%)Rest of the World 1,678 875 803 92%Total $19,529 $14,288 $5,241 37%SOURCE: Sonoma Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive SkinMarch 18, 2026 8:30 AM
ACCESS NewswireBOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the launch of Aquanil® AD, a hypochlorous acid based dermatology product line for sensitive skin, developed exclusively for Person & Covey, Inc. for distribution through its established over-the-counter dermatology channels in the United States. The Aquanil AD product line includes Aquanil AD Repair Mist, a soothing spray for irritated or damaged skin; Aquanil AD Recovery Gel, designed to help reduce the appearance of scars; and Aquanil AD Rescue Serum for relief from rashes, itching and irritation. Each product was specifically designed for sensitive or reactive skin."The incomparable safety profile of Sonoma's Microcyn technology made it an ideal choice for our Aquanil line and our commitment to providing relief for individuals with sensitive skin," remarked Marisa Brenninkmeyer, CEO of Person & Covey. "We are thrilled to make hypochlorous acid-based products available to our customers, as we know the dermatological benefits of HOCl.""We are excited to partner with such a highly regarded company as Person & Covey, whose dedication to those with sensitive skin aligns with Sonoma's mission to provide safe and effective skin care solutions," noted Amy Trombly, CEO of Sonoma. "We look forward to growing this partnership and sharing our technology with more consumers across the United States."About Sonoma Pharmaceuticals, Inc.Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.About Person & CoveyPerson & Covey, Inc. has been a pioneer in the field of health and personal care since its founding by chemist Lorne V. Person in 1941. The family-owned California-based company has grown with each generation to offer an ever-widening line of internationally distributed products. From its beginning, Person & Covey has worked closely with the medical community to develop high-quality therapeutic formulas, especially in the areas of sun protection and dermatological care. Today the company continues to create revolutionary products for use by medical professionals and their patients. Recognizing that each patient is unique, Person & Covey carefully crafts products that are appropriate for use by even the most sensitive of users. Through its commitment to combining cutting-edge science with cosmetic elegance, Person & Covey is proud to continue its tradition of providing outstanding health and beauty solutions. More information can be found at www.personandcovey.com.Forward-Looking StatementsExcept for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.Media and Investor Contact:Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.comWebsite: www.sonomapharma.comFollow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticalsFollow us on Instagram: https://www.instagram.com/sonomapharma_us/Follow us on Facebook: https://www.facebook.com/sonomapharma/SOURCE: Sonoma Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial ResultsFebruary 10, 2026 4:10 PM
ACCESS NewswireRevenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior yearNet loss and net loss per share decreased from prior year for both the three months and nine months ended December 31, 2025EBITDAS loss decreased by $0.4 million and $0.9 million for the three and nine months ended December 31, 2025 compared to prior year BOULDER, COLORADO / ACCESS Newswire / February 10, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended December 31, 2025."Sonoma is pleased to report another quarter of revenue growth, demonstrating continued execution of our strategic priorities," remarked Amy Trombly, CEO of Sonoma Pharmaceuticals. "We are continuing to strengthen our regulatory position in both the U.S. and international markets and to broaden our distribution network. We have also strengthened our leadership and governance by welcoming a new Audit Committee Chair and a Senior Vice President of Regulatory, Quality and Product Development, as we position Sonoma for long-term global leadership in hypochlorous acid."Business HighlightsSonoma continued to advance its regulatory initiatives, expand distribution channels, and strengthen its organizational leadership:On October 7, 2025, Sonoma announced that it had successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).On October 14, 2025, Sonoma announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, to be distributed into hospital systems, home healthcare and other healthcare channels across the United States.On November 13, 2025, Sonoma announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has earned the National Rosacea Society (NRS) Seal of Acceptance.On January 28, 2026, Sonoma announced the appointment of Vanessa Jacoby to its Board of Directors and Arturo Angel as its Senior Vice President of Regulatory, Quality and Product Development.Results for the Quarter Ended December 31, 2025Revenues for the quarter ended December 31, 2025 of $4.3 million increased by $0.7 million, or 22%, compared to $3.6 million for the same period last year. Revenues in the U.S. increased 98%, primarily as a result of an increase in sales of over-the-counter products and increasing sales by new and existing distributors. Europe revenues increased 24% as a result of increased demand for our products. Revenues in Asia increased 38% and Rest of World revenues decreased 11%. Revenues from these regions tend to fluctuate when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities. Latin America revenues decreased 38%, primarily due to timing of customer orders for overflow manufacturing.For the quarter ended December 31, 2025, Sonoma reported revenues of approximately $4.3 million and cost of revenues of $2.7 million, resulting in gross profit of $1.6 million, or 38% of revenue, compared to a gross profit of $1.3 million, or 36% of revenue, for the same period last year. Gross margins increased by 2% for the quarter ended December 31, 2025 when compared to the same period last year as a result of an increase in revenue and overall product mix.Total operating expenses during the quarter ended December 31, 2025 were $2.3 million, approximately flat when compared to $2.3 million during the same period in the prior year.Net loss before income taxes for the quarter was $0.9 million, compared to $0.9 million for the same period last year. EBITDAS loss for the quarter ended December 31, 2025 of $0.6 million decreased by $0.4 million, compared to an EBITDAS loss of $1.0 million for the same period last year.Results for the Nine Months Ended December 31, 2025Revenues of $14.0 million for the nine months ended December 31, 2025 increased by $3.5 million, or 33%, compared to $10.5 million for the same period last year. Revenues in the U.S. increased 90%, primarily as a result of an increase in sales of over-the-counter products and increasing sales by new and existing distributors. Europe revenues increased 31% as a result of increased demand for our products. Revenues in Asia increased 38% and Rest of World revenues increased 50%. Revenues from these regions tend to fluctuate when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities. Latin America revenues decreased 26%, primarily due to timing of customer orders for overflow manufacturing.For the nine months ended December 31, 2025, Sonoma reported revenues of $14.0 million and cost of revenues of $8.8 million, resulting in gross profit of $5.2 million, or 37% of revenues, compared to a gross profit of $3.9 million, or 37% of revenues, in the same period last year.Total operating expenses during the nine months ended December 31, 2025 of $7.3 million increased by $0.3 million, or 5%, compared to $7.0 million during the same period last year.Net loss before income taxes for the nine months ended December 31, 2025 was $2.9 million, compared to $2.4 million for the same period in the prior year. EBITDAS loss for the nine months ended December 31, 2025 of $1.9 million decreased by $0.9 million, compared to an EBITDAS loss of $2.8 million for the same period last year.About Sonoma Pharmaceuticals, Inc.Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.Forward-Looking StatementsExcept for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.Media and Investor Contact:Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.comWebsite: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts) December 31,2025 March 31,2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $2,561 $5,374 Accounts receivable, net 2,382 2,232 Inventories, net 3,703 2,915 Prepaid expenses and other current assets 3,351 1,915 Current portion of deferred consideration, net of discount 148 212 Total current assets 12,145 12,648 Property and equipment, net 314 225 Operating lease, right of use assets 642 84 Deferred tax asset, net 458 589 Deferred consideration, net of discount, less current portion - 73 Other assets 64 74 Total assets $13,623 $13,693 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $1,646 $953 Accrued expenses and other current liabilities 2,111 2,224 Deferred revenue, current portion 314 641 Short-term debt - 220 Operating lease liabilities, current portion 146 58 Total current liabilities 4,217 4,096 Deferred revenue, net of current portion - 17 Withholding tax payable 5,465 5,142 Operating lease liabilities, less current portion 509 27 Total liabilities 10,191 9,282 Commitments and Contingencies Stockholders' Equity: Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2025 and March 31, 2025, no shares issued and outstanding at December 31, 2025 and March 31, 2025 - - Common stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2025 and March 31, 2025, 1,730,613 and 1,634,265 shares issued and outstanding at December 31, 2025 and March 31, 2025, respectively - - Additional paid-in capital 207,023 206,593 Accumulated deficit (200,400) (197,806)Accumulated other comprehensive loss (3,191) (4,376)Total stockholders' equity 3,432 4,411 Total liabilities and stockholders' equity $13,623 $13,693 SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share amounts)
(Unaudited) Three Months EndedDecember 31, Nine Months EndedDecember 31, 2025 2024 2025 2024 Revenues $4,349 $3,564 $13,968 $10,534 Cost of revenues 2,699 2,294 8,734 6,597 Gross profit 1,650 1,270 5,234 3,937 Operating expenses: Research and development 557 427 1,726 1,403 Selling, general and administrative 1,771 1,874 5,618 5,588 Total operating expenses 2,328 2,301 7,344 6,991 Loss from operations (678) (1,031) (2,110) (3,054)Other (expense) income, net (271) 112 (812) 675 Net loss before income taxes (949) (919) (2,922) (2,379)Income tax benefit (expense) 130 (9) 328 (302)Net loss $(819) $(928) $(2,594) $(2,681) Net loss per share: basic and diluted $(0.48) $(0.63) $(1.56) $(2.40)Weighted-average number of shares outstanding: basic and diluted 1,713 1,464 1,667 1,117 Other comprehensive loss: Net loss $(819) $(928) $(2,594) $(2,681)Foreign currency translation adjustments 174 (357) 1,185 (1,831)Comprehensive loss $(645) $(1,285) $(1,409) $(4,512)SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited) Three Months EndedDecember 31, Nine Months EndedDecember 31, 2025 2024 2025 2024 (1) Loss from operations minus non-cash expenses EBITDAS loss: GAAP operating loss as reported $(678) $(1,031) $(2,110) $(3,054)Non-cash adjustments: Stock-based compensation 24 13 120 134 Depreciation 34 33 106 107 Non-GAAP income (loss) from operations minus non-cash expenses EBITDAS loss $(620) $(985) $(1,884) $(2,813) (2) Net loss minus non-cash and one-time expenses: GAAP net loss as reported $(819) $(928) $(2,594) $(2,681)Non-cash adjustments: Stock-based compensation 24 13 120 134 Non-cash foreign exchange transaction losses and other (income) and expense 292 (3) 1,278 (405))Income taxes expense (benefit) (130) 9 (328) 302 Depreciation 34 33 106 107 Non-GAAP loss minus non-cash expenses $(599) $(876) $(1,418) $(2,543) (3) Operating expenses minus non-cash expenses GAAP operating expenses as reported $2,328 $2,301 $7,344 $6,991 Non-cash adjustments: Stock-based compensation (24) (13) (120) (134)Depreciation (34) (33) (106) (107)Non-GAAP operating expenses minus non-cash expenses $2,270 $2,255 $7,118 $6,750 (1) Income (loss) from continuing operations minus non-cash expenses (EBITDAS) is a non-GAAP financial measure. The company defines operating income (loss) minus non-cash expenses as GAAP reported operating income (loss) minus operating depreciation and amortization, and operating stock-based compensation. The company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.(2) Net income (loss) minus non-cash and one time expenses is a non-GAAP financial measure. The company defines net income (loss) minus non-cash expenses as GAAP reported net income (loss) minus depreciation and amortization, stock-based compensation, forgiveness of PPP loan and non-cash foreign exchange transaction losses. The company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.(3) Operating expenses minus non-cash expenses is a non-GAAP financial measure. The company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
PRODUCT RELATED REVENUE SCHEDULES
(In thousands)
(Unaudited)The following table presents the company's disaggregated product revenues by geographic region: Three Months Ended December 31, Nine Months Ended December 31, 2025 2024 2025 2024 United States $1,218,000 $614,000 $3,672,000 $1,930,000 Europe 1,560,000 1,257,000 5,179,000 3,943,000 Asia 800,000 579,000 2,519,000 1,832,000 Latin America 518,000 829,000 1,614,000 2,174,000 Rest of the World 253,000 285,000 984,000 655,000 Total $4,349,000 $3,564,000 $13,968,000 $10,534,000 SOURCE: Sonoma Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product DevelopmentJanuary 28, 2026 4:15 PM
ACCESS NewswireBOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the appointment of Vanessa Jacoby, Chief Business and Financial Officer of Quanta Therapeutics, Inc., to its Board of Directors and to serve as Chair of its Audit Committee. Sonoma also announced the retirement of its longtime director, Dr. Jay Birnbaum. Finally, Sonoma announced the appointment of Arturo Angel as its Senior Vice President of Regulatory, Quality and Product Development.Vanessa Jacoby brings financial expertise along with extensive experience in the biotechnology and life science sectors to Sonoma's Board. She has served as a senior financial executive of several private and public companies and as an active participant on audit committees, responsible for reporting financial results and internal controls matters. Prior to joining Quanta, a clinical stage biotechnology company, Ms. Jacoby served as CFO of Shoreline Biosciences, where she played a key role in establishing two partnerships with Kite Pharma and BeiGene. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc. (NASDAQ: RNA), where she led all corporate finance and planning activities and played a key role in the company's initial public offering. Ms. Jacoby is a licensed CPA in the State of California and began her career as an auditor for Ernst & Young.Arturo Angel joins Sonoma from Bausch Health Companies Inc., where he served as Executive Director of Research & Development, leading product development of pharmaceutical, over-the-counter and cosmetic products for dermal, oral and nasal administration for over 15 years. Mr. Angel brings expertise in formulation development, product characterization, manufacturing process transfers, validations and scale-ups, product registrations and approvals. Prior to his tenure at Bausch Health, Mr. Angel began his career at Dow Pharmaceutical Sciences Inc. serving as a chemist and formulation and process development leader for pharmaceutical topical products for nearly 20 years.Effective January 28, 2026, Dr. Jay Birnbaum retired from our Board of Directors. Dr. Birnbaum has served as a member of Sonoma's Board of Directors since April 2007 and has provided invaluable contributions to Sonoma's growth during this time. Over his long career, Jay has been involved in the development and commercialization of numerous dermatological drugs and consumer products and brands and has been an industry consultant for the past 25 years. He is a co-founder and member of the Board of Directors of Hallux, Inc., and previously served as co-founder and Chief Medical Officer of Kythera Biopharmaceuticals, Vice President of Global Project Management at Novartis/Sandoz Pharmaceuticals Corporation, and various management positions at both the Medical and Consumer Products Divisions of American Cyanamid Company (Wyeth).Lead Independent Director, Jerry McLaughlin, commented, "Jay's wise counsel and common-sense approach have served our shareholders well. Jay always offered keen scientific guidance that blended soundly with our strategic business initiatives. I wish him success as he devotes his time to develop the emerging Birnbaum Vineyards and Winery in the Finger Lakes region of New York. Although he will be missed on the Board, Sonoma will continue to have the benefit of his support as a consultant to the Company.""We are truly honored to have both Ms. Jacoby and Mr. Angel join the Sonoma team," remarked Amy Trombly, CEO of Sonoma. "Each provides a level of expertise in their respective fields that we believe will be tremendously beneficial to Sonoma at this stage of our growth. We also sincerely thank Dr. Birnbaum for his contributions in making Sonoma what it is today. We are excited for this new chapter and looking forward to the future of our company and our Microcyn technology."About Sonoma Pharmaceuticals, Inc.Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.Forward-Looking StatementsExcept for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.Media and Investor Contact:Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.comWebsite: www.sonomapharma.comFollow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticalsFollow us on Instagram: https://www.instagram.com/sonomapharma_us/Follow us on Facebook: https://www.facebook.com/sonomapharma/SOURCE: Sonoma Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

$SNOA

Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
BOULDER, CO / ACCESS Newswire / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its HOCl-based diaper rash product for infants and children into large retailers in the United States.

The antimicrobial hydrogel is being marketed and sold through Sonoma's U.S.-based distribution partner. The diaper rash product is currently carried in 3,600 Walmart stores, Amazon.com, and certain large grocery chains.

"We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels," said Amy Trombly, CEO of Sonoma. "We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations."

SNOA........................................a/h

SNOA reports Tuesday 6/17

Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) to be sold through a prominent U.K. health and beauty retailer and pharmacy chain across more than 1,200 stores throughout the United Kingdom.

The innovative product line includes an acne toner and a balancing serum, both of which are available under the retailer's own brand name.

"We are excited to bring our safe and effective acne line to consumers in the United Kingdom and to expand our range of distribution in Europe," said Amy Trombly, CEO of Sonoma. "These products utilize all-natural hypochlorous acid and our patented Microcyn technology formulation, providing a safe and gentle alternative to products containing harsh ingredients such as alcohol and benzoyl peroxide."

SNOA..........................................a/h

SNOA.........................................https://stockcharts.com/h-sc/ui?s=SNOA&p=W&b=5&g=0&id=p86431144783

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)
BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its manufacturing facility and five of its products with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The newly registered products include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant.

"Thanks to the diligent efforts of our regulatory team in securing these new registrations with the MHRA, we are now able to bring our safe and effective Microcyn-based products to the United Kingdom," said Amy Trombly, CEO of Sonoma. "The U.K. represents a significant new market for Sonoma, for both our wound care and dermatology products, and we are excited for the opportunities for growth that this new registration provides."

SNOA............................................................a/h

SNOA......................................https://stockcharts.com/h-sc/ui?s=SNOA&p=W&b=5&g=0&id=p86431144783

2.73 + 30%

News Jan 29 ..2 year master supply agreement to large retailers 
Effective ..January 29, 2025, ...we entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation.. for the sale of Microcyn® technology-based products to large retailers in the United States. The agreement is for an initial term of two years, subject to three automatic one-year renewal periods..... 

SNOA ..)2.83 + 6% 

$3.05 trading whole float already?? 
WASHINGTON (AP) — US added a strong 227,000 jobs in November in bounce-back from October slowdown.

Older news diabetic ulcers common ... 05:39 PM EST, 11/11/2024 (MT Newswires) -- Sonoma Pharmaceuticals (SNOA) said late Monday the US Food and Drug Administration has granted a new 510(k) clearance for its Microcyn technology-based hydrogel for wound treatment.

SNOA $2.90s cooking something again 1m floater

Small gain but booked it. Along with very quick flips PFRX TRNR and a couple others. Back in NUKK it was a MoonMarket pick Bitcoin Jacobi investment play but failed $2 support.  Second time back in. If stopped out again so be it. Move on again. Always the next play. 

2.85 nice trade if you booked it

This one past $3.46 zone with 1m float $3.60- $4.06 up next and then $5s possible..


Recent Stock SplitsDateSymbolCompany NameTypeSplit RatioNov 18, 2024UPCUniverse Pharmaceuticals IncReverse1 for 15Nov 18, 2024SGNSigning Day Sports IncReverse1 for 48.01Nov 18, 2024LIFWMsp Recovery IncReverse1 for 25Nov 18, 2024BJDXBluejay Diagnostics Inc

$3.38 +38% missed the next zone $3.11- $3.46 all good in pennyland 

Back out at $3.08'lightning flips mandatory 

SNOA $2.90s picked up a few maybe they let it go this time 1m floater..

05:39 PM EST, 11/11/2024 (MT Newswires) -- Sonoma Pharmaceuticals (SNOA) said late Monday the US Food and Drug Administration has granted a new 510(k) clearance for its Microcyn technology-based hydrogel for wound treatment.The clearance allows the product to be used, under the supervision of a healthcare professional, for wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, first and second degree burns, diabetic ulcers, and mechanically or surgically-debrided wounds, the company said.The clearance applies to 50 milliliter bottles with a shelf life of 24 months, it said.

Took some $SNOA for a swing

Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line
The new eye care line will also feature refreshed design and improved packaging for Ocucyn® Eyelid & Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024

https://www.accesswire.com/915832/sonoma-pharmaceuticals-and-emc-pharma-announce-collaboration-to-co-market-an-expanded-eye-care-product-line

Bitcoin $100,000 coming :Go for cryptos again many reasons once they have mid morning sell off. Trump pushing Bitcoin also

ELWS MARA RIOT CAN HIVE BTCM BTDR BTCS
MATH CLSK WULF IREN ANY BITF ARBK HUT MIGI GREE BTBT MARA RIOT SOS SDIG COIN NUKK CGA OCTO CIFR LMFA BRRR

ZEO gap & trap
TBIO looks better
FRGT is a turd that cant hold its gains, look at the chart
https://finviz.com/quote.ashx?t=FRGT&p=d 👀

I cant do 4am anymore like you young people
Im old AF😆

Missing out on ZEO TBIO and FRGT wake up lol

TRADE BREAKDOWN ON $SNOA & $LUNR

LIKE & REPOST FOR MORE!! 💰💰 pic.twitter.com/IEzrxsHmlq— Tiger Line Trading (@TigerLineTrades) September 18, 2024

SNOA...OUT

SNOA MAGNET PASS1

SNOA...5.36 MAGNET

SNOA...READY TO GO

Low Float NASDAQ Compliance play

SNOA....PUSHING INTO CLOSE

SNOA..POST SPLIT SHOWING SIGNS

SNOA READY TO RUMBLE

SNOA POST SPLIT BEAST

SNOA .36

SNOA hit .24

SNOA...........................https://stockcharts.com/h-sc/ui?s=SNOA&p=W&b=5&g=0&id=p86431144783

Upcoming Events ---->
https://sonomapharma.com/sonoma-events-tradeshows/

GO $SNOA

Investor Presentation From April 9, 2024 ---->
https://d1io3yog0oux5.cloudfront.net/_f4a411dced9e94f2fedfb7f057423722/sonomapharma/db/359/2900/pdf/Sonoma+Presentation+4.9.24+Website+Version.pdf

GO $SNOA

bottom

.16-.25

$1.7M OFFERING @ .20
https://dilutiontracker.com/app/search/SNOA

😁

SNOA new 52 week low

SNOA new 52 week low